Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | TPSAB1 | Q15661 | 5/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.48 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14485267 | 0.99 | KMT2A (0.57) | KMT2AEPHX2TPSAB1PRSS1TPSD1 | |
| SCHEMBL6421736 | 0.90 | KMT2A (0.49) | KMT2AEPHX2TPSAB1PRSS1TPSD1 | |
| SCHEMBL31010055 | 0.90 | KMT2A (0.55) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL2057615 | 0.90 | KMT2A (0.55) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL3177417 | 0.89 | KMT2A (0.62) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL31652901 | 0.88 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL2744319 | 0.88 | KMT2A (0.55) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL15948331 | 0.87 | KMT2A (0.53) | KMT2AEPHX2TPSAB1FABP7FABP5 | |
| SCHEMBL118108 | 0.86 | KMT2A (0.56) | KMT2AEPHX2CASP3FABP7FABP5 | |
| SCHEMBL525564 | 0.86 | KMT2A (0.59) | KMT2AEPHX2CASP3FABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3788039-B1 | FACTOR XIIA INHIBITORS | UNIV LEEDS INNOVATIONS LTD (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-12336991-B2 | Factor XIIA inhibitors | UNIVERSITY OF LEEDS (GB) | 2025-06-24 | — | — | US | disclosed |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2022-09-29 | — | — | US | disclosed |
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2021-03-25 | — | — | US | disclosed |
| EP-3788039-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-03-10 | — | — | EP | disclosed |
| EP-3773555-A1 | FACTOR XIIA INHIBITORS | University of Leeds (GB) | 2021-02-17 | — | — | EP | disclosed |
| CN-112204023-A | Factor XIIa inhibitors | 利兹大学 | 2021-01-08 | — | — | CN | disclosed |
| CN-112165938-A | Factor XIIA inhibitors | 利兹大学 | 2021-01-01 | — | — | CN | disclosed |
| EP-2729443-B3 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019186164-A1 | FACTOR XIIA INHIBITORS | UNIVERSITY OF LEEDS (GB) | 2019-10-03 | — | — | WO | disclosed |
| US-9234000-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-01-12 | — | — | US | disclosed |
| EP-2729443-B1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-11-25 | — | — | EP | disclosed |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2015-08-13 | — | — | US | disclosed |
| US-9051249-B2 | Benzylamine derivatives as inhibitors of plasma kallikrein | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2015-06-09 | — | — | US | disclosed |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-31 | — | — | US | disclosed |
| EP-2729443-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013005045-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2013-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087172-A1 | FACTOR XIIa INHIBITORS | F11, F13B, F12 | KMT2A 2727/4885EPHX2 647/4885TPSAB1 134/4885 |
| US-20150225450-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KMT2A 742/4885EPHX2 1235/4885TPSAB1 22/4885 |
| US-20220305011-A1 | FACTOR XIIA INHIBITORS | F11, F13B, F12 | KMT2A 1815/4885EPHX2 199/4885TPSAB1 136/4885 |
| US-12336991-B2 | Factor XIIA inhibitors | F11, F13B, F12 | KMT2A 1815/4885EPHX2 199/4885TPSAB1 136/4885 |
| US-20140213611-A1 | BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, BDKRB1 | KMT2A 742/4885EPHX2 1235/4885TPSAB1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.